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Introduction
Tuberous sclerosis complex (TSC) is an autosomal
dominant disorder, with an incidence of approximately
1 in 6000. It arises from a genetic abnormality
involving either the TSC1 gene on chromosome 9, or
the TSC2 gene on chromosome 16. The protein
product of the TSC1 gene is hamartin and that of
TSC2 is tuberin. In cells, hamartin and tuberin form a
complex, which inhibits the mammalian target of
rapamycin (mTOR), a central controller of cell
growth and proliferation [1].
Renal angiomyolipomas (AML) occur in 80% of
patients with TSC. These lesions are composed of
abnormal blood vessels, smooth muscle and fat cells
and they have a tendency to bleed spontaneously,
which can lead to life-threatening haemorrhagic shock
[2]. Here we report on a patient with TSC suffering
from recurrent severe haemorrhage from both kidneys
due to extensive AML formation. Because of massive
haemorrhage the patient was nephrectomized on the
right side. One year later, the remaining left kidney was
removed and a pre-emptive living renal transplantation
was performed at the same time to prevent further
renal haemorrhage.
Case
A 15-year-old, and till then a healthy young woman
was evaluated in the year 2000 for abdominal pain
after an injury which occurred while playing soccer. On
clinical evaluation, small blisters (facial angiofibromas)
were noted in her face and urine examination revealed
microhaematuria. Kidney function was in the normal
range and no proteinuria was detected. Computerized
tomography (CT) scan of the abdomen showed
enlargement of both kidneys with diffuse hypodense
areas corresponding to multiple AMLs and isolated
haematomas. A magnetic resonance imaging (MRI)
scan revealed subependymal nodules in the brain. As
the mother also showed facial angiofibromas and the
brother was known to have diffuse bilateral AMLs in
the kidneys, a clinical diagnosis of TSC was made.
A genetic examination (Institute of Human Genetics,
University Heidelberg, Germany) of the patient and
her mother revealed a novel nonsense mutation
(c. 408C>A, Y130X) in the TSC2 gene, confirming
the clinical diagnosis.
At the age of 17 years, the patient presented with a
low haemoglobin level and a large spontaneous
subcapsular haematoma was found in the left kidney
(Figure 1A). This was treated conservatively but 1 year
later, spontaneous bleeding recurred in the same
kidney, with a drop in the haemoglobin concentration
to 66 g/l. The estimated glomerular filtration rate
(GFR) according to the Cockcroft–Gault formula was
78ml/min. An abdominal CT scan revealed persistence
of the extensive subcapsular haematoma in the left
kidney. A catheter embolization of the left upper pole
artery was performed to stop bleeding. Despite arterial
embolization, repeated spontaneous bleeding occurred
in the left kidney, necessitating numerous blood
transfusions to correct anaemia in the following 2 years.
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In January 2005, bleeding occurred for the first time
in the right kidney, causing a profound drop of the
haemoglobin level. The serum creatinine increased to
210 mmol/l (MDRD GFR 28ml/min). A transarterial
right kidney embolization was performed to stop the
bleeding. During embolization extensive retroperito-
neal bleeding occurred and the patient was admitted to
the intensive care unit (ICU) for haemodynamic
and respiratory stabilization. In the following days,
the patient developed an abdominal compartment
syndrome, sepsis and acute respiratory distress syn-
drome (ARDS). Kidney function declined rapidly and
the patient became anuric. After 28 days in the ICU, an
abdominal CT scan identified gas in the right-sided
haematoma. An infection with anaerobic bacteria was
suspected and the haematoma was evacuated and the
right kidney removed. Following this intervention,
clinical improvement occurred quickly and the patient
was discharged with an estimated GFR (MDRD
formula) of 34ml/min. Thirty-three units of packed
red blood cells and 14 units of fresh frozen plasma
(FFP) were transfused during the stay in the ICU to
stabilize cardiovascular function.
Kidney function subsequently remained stable and
the patient felt well, except for intermittent left lower
back pain. Since the patient lived in a remote area and
since there was a high risk for a new life-threatening
bleeding in the left kidney, a decision was made to
remove the remaining left kidney and to perform a
living kidney transplantation from her 50-year-old
healthy aunt.
The post-transplant course was uneventful and renal
allograft function was excellent with a standard
immunosuppressive regime consisting of tacrolimus,
mycophenolate mofetil and prednisone. An allograft
biopsy performed 3 months after transplantation
showed no signs of rejection or calcineurin inhibitor
toxicity. It has been reported that treatment with
mTOR inhibitors has a favourable effect on extrarenal
manifestation of TSC. MRI scan of the cortex revealed
several subependymal nodules and cortical tubers with
a maximal diameter of 10mm in our patient.
Subependymal giant cell tumours (SGCTs) arise from
pre-existing subependymal nodules and can show
massive haemorrhage, rapid growth and malignant
transformation in adult patients. In a preliminary
clinical trial, rapamycin was associated with regression
of SGCT and in one patient, regrowth of SGCT after
interruption of rapamycin treatment [3]. These promis-
ing results encouraged us to switch the immunosup-
pression from tacrolimus to rapamycin, in an
attempt to prevent neurological complications in our
patient. An MRI scan of the brain 6 months into
treatment with rapamycin showed no progression
of the subependymal nodules and cortical tubers,
suggesting that rapamycin stabilized disease progres-
sion. Furthermore, after switching to rapamycin,
the MDRD GFR increased from 40 to 48ml/min,
which is in line with the known beneficial effect of a
calcineurin-free immunosuppression on graft function.
Pathological examination of left kidney
Macroscopic examination of the resected left kidney
showed a replacement of virtually the entire renal
tissue by a huge AML (Figure 1B). Careful micro-
scopical examination of the kidney (diametre 15 cm)
unexpectedly revealed the presence of a renal cell
carcinoma (RCC) within the AML (Figure 2A). This
RCC was sharply demarcated with a diametre of
1.9 cm. It was classified as stage pT1a cN0 cM0,
Fuhrman grade III. The tumour consisted of epithe-
lioid cells with granular cytoplasm and perinuclear
halo (Figure 2B). Hale’s colloidal iron staining was
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Fig. 1. Renal Manifestations of TSC. (A) CT scan of the abdomen in the year 2002, which shows large kidneys with multiple
angiomyolipomas and a subcapsular haematoma (double asterisk) in the left kidney. (B) Macroscopic view of the left kidney after
nephrectomy; co-existence of RCC (arrows) and angiomyolipomatous tissue.
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only focally positive. Immunohistochemically, the
RCC showed absence of HMB-45 and actin, whereas
the surrounding AML was HMB-45 and actin positive
(Figure 2C). The RCC also showed expression
of vimentin and cytokeratin, but was negative for a
RCC-specific antibody (RCC marker) and epithelial
membrane antigen (EMA). This unusual histology
was neither characteristic for a clear cell RCC
(granular cytoplasm) nor a chromophobe RCC
(vimentin expression). Therefore, this RCC could not
be definitively classified.
Discussion
Here we report on a case of a young patient with TSC
and severe bleeding from AML in both kidneys, who
was nephrectomized and pre-emptively transplanted
with success.
Renal pathologies in patients with TSC include
AML, renal cysts and epithelial neoplasms [2]. Renal
AML are fat-containing tumours, which are associated
with a strong risk of haemorrhage due to the presence
of abnormal vessels and pseudoaneurysms. AML
occur in up to 80% of patients with TSC and are the
cause of substantial morbidity. AML associated with
TSC tend to be larger, bilateral, multifocal and present
at a younger age compared with sporadic forms [4].
They can be diagnosed from a characteristic radi-
ological pattern with the demonstration of fatty tissue
in CT or MRI scans. A novel mutation, C>A
transversion at c.408 in exon 4 of TSC2 (Y130X) was
found in the patient and her mother. This nonsense
mutation will truncate the gene product of TSC2.
Compared with TSC1, mutations in TSC2 are known
to cause a more severe clinical phenotype, which is
consistent with our case [5]. Thus, in our patient, renal
AMLs with a diameter of >4 cm were found in both
kidneys, a finding which is very rare or not seen at all
in TSC1 patients.
The risk of spontaneous bleeding is roughly corre-
lated with the size of the AML, though there is
substantial variation [6]. In our patient, the risk for the
recurrence of life-threatening bleeding was very high.
The remaining left kidney caused repetitive serious
bleeding episodes originating from numerous large
AML, some of them with a diameter >4 cm. AML
more than 4 cm in diameter are associated with a high
risk for symptomatic bleeding.
The therapeutic options to prevent bleeding from
renal AML are limited. It has been suggested that large
AML need to be surgically reduced or resected, or
should be managed by catheter embolization to deprive
the AML of its blood supply [7]. Bleeding complica-
tions from angiographic and surgical interventions
often necessitate the removal of the entire kidney to
control bleeding, as also occurred in our patient.
Retroperitoneal bleeding is a well-known complication
of AML, sometimes leading to death (‘Wunderlich
syndrome’). The nephrectomy of both kidneys repre-
sents a definitive treatment, but it implies subsequent
haemodialysis treatment.
Up to now, 38 renal transplantations have been
reported in TSC patients. In general patient outcome
was good, with functioning allografts in 32 of 38
patients with a follow-up of up to 14 years [8]. It has
been recommended that renal transplantation should
be accompanied by nephrectomy of both kidneys, to
remove the risk of malignant transformation and
tumour growth associated with immunosuppression.
Given the high risk for a recurrence of serious renal
bleeding, the psychological burden for the patient and
the family and the availability of a living kidney donor,
the decision was made for our patient to remove the
remaining left kidney, in combination with a living
renal transplantation.
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Fig. 2. Histology of renal AML and RCC. (A) The typical histomorphological characteristics of AML with smooth muscle and vessels (H &
E stain, original magnification 15). (B) histological presentation of the incidentally diagnosed RCC. Epithelioid tumour cells with granular
cytoplasm (chromophobe-like) (original magnification 400). (C) HMB-45 expression of the AML (on the right) and lack of expression in the
RCC (on the left) (original magnification 15).
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The occurrence of RCC is a rare but well-known
complication of TSC, that occurs in 1–2% of patients
[2]. However, some of the previously reported RCC in
tuberous sclerosis were later diagnosed as epithelioid
AML, suggesting that the incidence of tuberous
sclerosis-associated RCC is lower than some have
suggested. Epithelioid AML represent an unusual
subtype of AML, which is characterized by prolifera-
tion of predominantly epithelioid cells. In contrast to
the triphasic (classic) AML, epithelioid AML can show
a malignant behaviour. These tumours have a striking
resemblance to RCC and often have high-grade
histological features. Recently, it was shown that
AML are associated with melanosome-associated
protein (HMB-45) immunoreactivity, and that the
HMB-45 expression is useful in differential diagnosis
between AML and other tumours [9]. In our case,
negative HMB-45 immunoreactivity was diagnostic for
an RCC. The co-existence of AML and renal epithelial
neoplasia is uncommon, with slightly more than 50
reported cases in the literature [10]. Pathological
analysis of these case reports is difficult, because
most have been published as clinical cases, lacking a
detailed pathological description or exact histological
typing. In addition, most of these cases were published
before epithelioid AML was recognized as a separate
entity. Few of the cases reported as clear-cell RCC
were later reclassified as epithelioid AML.
According to the literature, in sporadic cases as well
as in the setting of tuberous sclerosis, the most
common renal cell neoplasm is clear-cell RCC. In
patients with tuberous sclerosis, there is also a high
frequency of oncocytomas. In a previous study, a large
number of chromophobe-like RCC was detected in
patients with tuberous sclerosis. Similarly, in previous
reported cases in the literature of co-existing AMLs
and renal epithelial neoplasia, an unusually high
incidence of oncocytomas associated with AMLs is
also seen (12%). The RCC in our patient could not be
assigned to one of the 2004 WHO categories. Also in
our case, the tumour showed chromophobe-like
features. The granular cytoplasm was suggestive of a
chromophobe-like RCC, but the vimentin expression
excluded this diagnosis. All previously reported cases
of co-existent AMLs and renal cell neoplasia in
patients with tuberous sclerosis have been oncocyto-
mas, or were of the clear-cell RCC, chromophobe-like
or unclassified type.
The TSC1–TSC2 protein complex tunnels signals
from growth factors, cell cycle and nutrients to
regulate the activity of the downstream kinases
mTOR, p70S kinase, 4E-BP1 and ribosomal S6
proteins. In tumour cells of TSC patients the mTOR
pathway is aberrantly activated. In a mouse model for
TSC, tumour size in the kidneys regressed with the
treatment of the mTOR-specific inhibitor rapamycin
[11]. Recent studies in humans demonstrated
regression of renal AMLs during the administration
of rapamycin to a patient with TSC and a regrowth
when rapamycin was withdrawn [12]. Rapamycin is
therefore a potential therapeutic agent and clinical
trials of rapamycin in patients with TSC and AML are
ongoing. Because of the history of repetitive renal
bleeding necessitating nephrectomy, our patient would
not have qualified for these clinical trials.
In summary, in patients with TSC, large renal AML
can cause life-threatening abdominal bleeding.
Combined nephrectomy and living renal transplanta-
tion removes the risk of severe bleeding, and represents
definitive treatment in our patient.
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